Skip to main content
. Author manuscript; available in PMC: 2014 Sep 30.
Published in final edited form as: Nat Protoc. 2014 Feb 27;9(3):694–710. doi: 10.1038/nprot.2014.044

Figure 10.

Figure 10

Expected results. (a) Characterization of the CTC-iChip protocol shows high yield of spiked cancer cells isolated from whole blood that is independent of spiked cell type with low number of nucleated cell impurities. Mean yield: 97 ± 2.7% (± s.d.). (b) Logarithmic plot of the number of nucleated cell impurities after application of the CTC-iChip to healthy donor samples and clinical samples from patients of breast and pancreatic cancers. Mean carryover: 1,200 ± 900 (± s.d.) nucleated cells/ml of blood. Box plots were generated using JMP (SAS Institute) with the following settings: boxes represent first and third quartiles, lines represent upper and lower data points and exclude outliers. (c) Fluorescence micrographs of CTCs and impurities from the CTC-iChip product (20× objective, Nikon). Rare cell suspension is immobilized using Spintrap (Supplementary Fig. 1), fixed using 4% (wt/vol) paraformaldehyde and stained for immunofluorescence microscopy using antibodies against cytokeratins (CK; red, CTC marker), CD45 (green, leukocyte marker) and DAPI (nuclear stain, blue). Bright green dots indicate anti-CD45–coated magnetic beads.